
    
      To investigate the clinical outcomes for inflammation, visual acuity and macular thickness
      after treatment with Prolensa (bromfenac ophthalmic solution) 0.07% QD in subjects who have
      undergone cataract extraction with posterior chamber intraocular lens implantation.
    
  